Stryker Co. (NYSE:SYK) Shares Bought by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. increased its position in Stryker Co. (NYSE:SYK) by 0.7% in the fourth quarter, Holdings Channel reports. The firm owned 17,492 shares of the medical technology company’s stock after purchasing an additional 128 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Stryker were worth $5,245,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of SYK. Strategic Blueprint LLC grew its stake in Stryker by 39.8% in the third quarter. Strategic Blueprint LLC now owns 980 shares of the medical technology company’s stock worth $268,000 after purchasing an additional 279 shares in the last quarter. Coastline Trust Co boosted its stake in Stryker by 26.1% in the third quarter. Coastline Trust Co now owns 1,470 shares of the medical technology company’s stock valued at $402,000 after acquiring an additional 304 shares during the period. UMB Bank n.a. boosted its stake in Stryker by 0.7% in the third quarter. UMB Bank n.a. now owns 7,767 shares of the medical technology company’s stock valued at $2,122,000 after acquiring an additional 57 shares during the period. Handelsbanken Fonder AB boosted its stake in Stryker by 3.5% in the third quarter. Handelsbanken Fonder AB now owns 108,866 shares of the medical technology company’s stock valued at $29,750,000 after acquiring an additional 3,693 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC boosted its stake in Stryker by 10.2% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 820 shares of the medical technology company’s stock valued at $224,000 after acquiring an additional 76 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Allan C. Golston sold 3,273 shares of the stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the sale, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The disclosure for this sale can be found here. In the last 90 days, insiders sold 212,109 shares of company stock worth $72,845,768. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research reports. TD Cowen lifted their target price on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Citigroup lifted their target price on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada lifted their target price on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Truist Financial lifted their target price on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research note on Wednesday, January 31st. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and lifted their price target for the company from $315.00 to $360.00 in a report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $340.67.

Stryker Stock Performance

SYK opened at $335.61 on Friday. The company has a market capitalization of $127.69 billion, a price-to-earnings ratio of 40.68, a price-to-earnings-growth ratio of 2.71 and a beta of 0.89. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The business has a 50 day moving average price of $348.88 and a two-hundred day moving average price of $314.88.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.00 earnings per share. Research analysts predict that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a $0.80 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.95%. Stryker’s dividend payout ratio (DPR) is 38.79%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.